{
  "docId": "019de075-5029-738c-8512-9456f77efe7c",
  "docSlug": "25c628cfc0779f52594519f9e322dc70",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 38,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "Data table presents ORR, Duration of Response, CA-125 response, PFS, and OS across patient subgroups.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5029-738c-8512-9456f77efe7c/13",
  "deckHref": "/decks/019de075-5029-738c-8512-9456f77efe7c",
  "deckJsonHref": "/decks/019de075-5029-738c-8512-9456f77efe7c.json",
  "deckAnchorHref": "/decks/019de075-5029-738c-8512-9456f77efe7c#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.25,
        "x": 0.04,
        "y": 0.215
      },
      "kind": "callout",
      "text": "Key Clinical Takeaways",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85f181b6-edb9-4fef-af8d-3125850795cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.48,
        "x": 0.48,
        "y": 0.7
      },
      "kind": "disclaimer",
      "text": "*Baseline for ORR & PFS evaluation is the timepoint immediately prior to starting post-Olvi-Vec carboplatin doublet +/- bevacizumab to allow direct comparison to historical data or patients' own previous line of chemotherapy. **Eligible for evaluation: with at least 1 measurable target lesion at baseline; including 2 patients without post-chemo scan after virotherapy, and therefore are assigned to the 'inevaluable for response' category per RECIST1.1. ^Including 3 unconfirmed; 2 in resistant and 1 in refractory groups",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2762819a-0632-40d0-bf63-9ff884020426",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Promising ORR and PFS, and clinical reversal of platinum resistance and refractoriness among patients with PRROC. All patients had documented progressive disease at enrollment. Overall response rate in 27 patients was 54% with 7.6-month median duration of response. Historical PFS in this patient population is ~4 mos",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ef6e7f6-7411-4e86-bce1-b07fcfde5fe7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.6,
        "x": 0.36,
        "y": 0.275
      },
      "kind": "table",
      "text": "Overall Response Rate (ORR) & Progression-Free Survival (PFS)*",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b916dfe3-6e3c-4730-bca5-2a9f97762a95",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Clinically-Meaningful Responses in Heavily Pretreated Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04ba4a9a-afac-4135-83bd-4e8e02b90d9d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "db902e75-7563-4198-9fcb-894c9ea66b6e",
      "evidence": "list/bullet: Promising ORR and PFS, and clinical reversal of platinum resistance and refractoriness among patients with PRROC.",
      "confidence": 0.7
    },
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "5e845c11-8339-43a8-8682-da5871495ce4",
      "evidence": "table/data: Overall Response Rate (ORR) & Progression-Free Survival (PFS)*",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 12,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "111fab6b-cd67-49dd-a414-d1390f2ab5d3",
      "evidence": "The presentation presents data on the clinical reversal of platinum resistance and refractoriness among patients with PRROC, highlighting the potential benefits of using Olvi-Vec.",
      "position": 0,
      "objective": "To highlight the cost of not using Olvi-Vec, specifically the limited treatment options for patients with platinum-resistant or platinum-refractory ovarian cancer",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}